Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F11%3A00369512" target="_blank" >RIV/86652036:_____/11:00369512 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/s10456-011-9213-5" target="_blank" >http://dx.doi.org/10.1007/s10456-011-9213-5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10456-011-9213-5" target="_blank" >10.1007/s10456-011-9213-5</a>
Alternative languages
Result language
angličtina
Original language name
Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress
Original language description
Cancer cells produce galectin-1 as a tumor promoting protein. Thiodigalactoside (TDG) as a non-metabolised drug, is shown to suppress tumor growth by inhibiting cancer enhancing activities of galectin-1, including immune cell dysregulation, angiogenesisand protection against oxidative stress. Using B16F10 melanoma and 4T1 orthotopic breast cancer models, intratumoral injection of TDG significantly raised the levels of infiltrating CD8(+) lymphocytes and reduced CD31(+) endothelial cell content, reducing tumor growth. TDG treatment of tumors in Balb/c nude mice reduced angiogenesis and slowed tumor growth by a third less than in immunocompetent mice. Knocking down galectin-1 expression (G1KD) significantly impeded tumor growth and the sensitivity of the G1KD tumors to TDG was severely reduced. Endothelial cells were protected by galectin-1 from oxidative stress-induced apoptosis, but TDG inhibited this antioxidant protective effect of galectin-1 and reduced tube forming activity.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Angiogenesis
ISSN
0969-6970
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
3
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
15
Pages from-to
293-307
UT code for WoS article
000293922300007
EID of the result in the Scopus database
—